<DOC>
	<DOCNO>NCT01379469</DOCNO>
	<brief_summary>The primary objective determine medication Carbamazepine , use therapy patient severe liver disease due Alpha-1-Antitrypsin Deficiency .</brief_summary>
	<brief_title>Carbamazepine Severe Liver Disease Due Alpha-1 Antitrypsin Deficiency</brief_title>
	<detailed_description>The primary objective determine Carbamazepine therapy patient severe liver disease due Alpha-1-Antitrypsin Deficiency lead significant reduction hepatic accumulation ATZ . The objective : To determine whether Carbamazepine treatment reduces hepatic fibrosis alpha-1-antitrypsin deficient patient severe liver disease . To determine whether Carbamazepine treatment reduces portal pressure alpha-1-antitrypsin deficient patient severe liver disease . To determine whether Carbamazepine treatment safe tolerate patient severe liver disease cause alpha-1-deficiency . To determine whether Carbamazepine treatment lead stabilization disease severity measure MELD score .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Age great equal 14 year less equal 80 year age . Alpha1Antitrypsin deficiency confirm ZZ SZ phenotype &amp; serum level &lt; 83mg/dl . HVPG great equal 10 mmHg unless collateral vessel visualize via transvenous biopsy . Child Pugh Score great equal 12 . Serum total bilirubin &gt; 5 mg/dl . INR &gt; 2.2 .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Carbamazepine ( Tegretol ) use</keyword>
	<keyword>severe liver disease</keyword>
	<keyword>alpha-1-antitrypsin deficiency</keyword>
</DOC>